AFMD

Affimed N.V.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$114.1M

Burn Rate (Qtr)

$7M

Company Profile

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

AFM13-202 (REDIRECT)

CD-30 positive peripheral T cell lymphoma (PTCL)

Phase 2 Intermin Data

H1 2021

AFM24 (tumor target EGFR)

Multiple solid tumors

Phase 1/2A

TBD

AFM13 + NK (CD30 target)

CD30-positive lymphoma (AFM13-104)

Phase 1

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon